Format

Send to

Choose Destination
J Am Coll Cardiol. 2014 Oct 7;64(14):1441-8. doi: 10.1016/j.jacc.2014.07.956.

Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress.

Author information

1
Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal Heart Institute Research Center, Montreal, Quebec, Canada. Electronic address: anil.nigam@icm-mhi.org.
2
Department of Medicine, Montreal Heart Institute, Université de Montréal, Montreal Heart Institute Research Center, Montreal, Quebec, Canada.
3
Coordinating Center and Université de Montréal, Montreal, Quebec, Canada.
4
Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada.
5
Department of Cardiology, Quebec Heart and Lung Institute, Quebec, Quebec, Canada.
6
Division of Cardiology, Mayo Clinic, Rochester, Minnesota.
7
McGill University Health Centre, Montreal, Quebec.

Abstract

BACKGROUND:

Recent trials of fish oil for the prevention of atrial fibrillation (AF) recurrence have provided mixed results. Notable uncertainties in the existing evidence base include the roles of high-dose fish oil, inflammation, and oxidative stress in patients with paroxysmal or persistent AF not receiving conventional antiarrhythmic (AA) therapy.

OBJECTIVES:

The aim of this study was to evaluate the influence of high-dose fish oil on AF recurrence, inflammation, and oxidative stress parameters.

METHODS:

We performed a double-blind, randomized, placebo-controlled, parallel-arm study in 337 patients with symptomatic paroxysmal or persistent AF within 6 months of enrollment. Patients were randomized to fish oil (4 g/day) or placebo and followed, on average, for 271 ± 129 days.

RESULTS:

The primary endpoint was time to first symptomatic or asymptomatic AF recurrence lasting >30 s. Secondary endpoints were high-sensitivity C-reactive protein (hs-CRP) and myeloperoxidase (MPO). The primary endpoint occurred in 64.1% of patients in the fish oil arm and 63.2% of patients in the placebo arm (hazard ratio: 1.10; 95% confidence interval: 0.84 to 1.45; p = 0.48). hs-CRP and MPO were within normal limits at baseline and decreased to a similar degree at 6 months (Δhs-CRP, 11% vs. -11%; ΔMPO, -5% vs. -9% for fish oil vs. placebo, respectively; p value for interaction = NS).

CONCLUSIONS:

High-dose fish oil does not reduce AF recurrence in patients with a history of AF not receiving conventional AA therapy. Furthermore, fish oil does not reduce inflammation or oxidative stress markers in this population, which may explain its lack of efficacy. (Multi-center Study to Evaluate the Effect of N-3 Fatty Acids [OMEGA-3] on Arrhythmia Recurrence in Atrial Fibrillation [AFFORD]; NCT01235130).

KEYWORDS:

arrhythmia; fibrillation; inflammation; omega-3 fatty acids; oxidative stress

PMID:
25277614
DOI:
10.1016/j.jacc.2014.07.956
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center